Skip to main content
Top
Published in: Endocrine 2/2020

01-05-2020 | Acromegaly | Original Article

Long-term real-life outcomes in a georrefered cohort of acromegalic patients in Brazil

Authors: Lara Benigno Porto, José Wilson Corrêa Rosa, João Willy Corrêa Rosa, Luiz Augusto Casulari, Ivan Ricardo Zimmermann, Luciana Ansaneli Naves

Published in: Endocrine | Issue 2/2020

Login to get access

Abstract

Purpose

Epidemiological data on acromegaly therapeutic outcomes in real-life conditions are scarce in Brazil. Information on the geographical accessibility to the dispensation of medicines and its impact on biochemical control is also poorly known. We aimed to describe the clinical outcomes of long-term therapy in patients with acromegaly at a referral medical centre in Brazil and to perform a spatial analysis of patients according to the distance from home to the drug-dispensing pharmacies aiming to evaluate its impact on biochemical control.

Methods

Global retrospective data analysis of 111 patients followed at the University Hospital of Brasília from January 1980 to March 2015 was performed, as well as a separate review of 17 new cases operated on from April 2015 to June 2019 according to surgery results. Spatial analysis of patients under pharmacological treatment applying Geographic Information System (GIS) software (ArcGIS, ESRI, Redlands, CA) was performed.

Results

Considering surgery alone, the cure rate was 23% from 1980 to 2015 and 29.4% from 2015 to 2019. In the long-term follow-up of the 111 patients from 1980 to 2015, 25.2% (n = 29) were cured, 40.6% (n = 44) presented controlled disease and 34.2% (n = 38) were biochemically uncontrolled after a period of follow-up of 8.9 ± 6.4 years. Biochemical control obtained in patients on pharmacological treatment (n = 76) was 58% (n = 44) after 5.8 ± 3.8 years. The distance from home to the drug-dispensing pharmacy did not influence biochemical control (p = 0.7616).

Conclusions

Most patients presented with disease under control. No evidence on the effect of the distance between home and drug-dispensing pharmacies on biochemical control was obtained.
Literature
1.
go back to reference A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. North Am. 37(1), 101–122 (2008) A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. North Am. 37(1), 101–122 (2008)
2.
go back to reference P. Chanson, S. Salenave, P. Kamenicky, L. Cazabat, J. Young, Acromegaly. Best. Pr. Res Clin. Endocrinol. Metab. 23, 555–574 (2009)CrossRef P. Chanson, S. Salenave, P. Kamenicky, L. Cazabat, J. Young, Acromegaly. Best. Pr. Res Clin. Endocrinol. Metab. 23, 555–574 (2009)CrossRef
3.
go back to reference A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M.G. Giraldo, A.C. Pinedo et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19, 448–457 (2016)CrossRef A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M.G. Giraldo, A.C. Pinedo et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19, 448–457 (2016)CrossRef
4.
go back to reference A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRef A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRef
5.
go back to reference H.J. Schneider, C. Sievers, B. Saller, H.U. Wittchen, G.K. Stalla, High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf.) 69, 432–435 (2008)CrossRef H.J. Schneider, C. Sievers, B. Saller, H.U. Wittchen, G.K. Stalla, High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf.) 69, 432–435 (2008)CrossRef
7.
go back to reference S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009) S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009)
8.
go back to reference L. Katznelson, E.R. Laws, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)CrossRef L. Katznelson, E.R. Laws, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)CrossRef
9.
go back to reference L.V. Neto, J. Abucham, A.L. Araujo, L. Boguszewski, D. Bronstein, M. Czepielewski, M. Recomendações, do Departamento de Neutoendrocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento de acromegalia no Brasil. Arq Bras Endocrinol. Metab. 55, 91–105 (2011)CrossRef L.V. Neto, J. Abucham, A.L. Araujo, L. Boguszewski, D. Bronstein, M. Czepielewski, M. Recomendações, do Departamento de Neutoendrocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento de acromegalia no Brasil. Arq Bras Endocrinol. Metab. 55, 91–105 (2011)CrossRef
10.
go back to reference A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRef A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRef
11.
go back to reference F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, D.R. Clemmons, A. Giustina, Expert consensus document: statement on acromegaly therapeutics outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2018)CrossRef F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, D.R. Clemmons, A. Giustina, Expert consensus document: statement on acromegaly therapeutics outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2018)CrossRef
12.
go back to reference M. Buchfelder, S.-M. Schlaffer, The surgical treatment of acromegaly. Pituitary 20, 76–83 (2017)CrossRef M. Buchfelder, S.-M. Schlaffer, The surgical treatment of acromegaly. Pituitary 20, 76–83 (2017)CrossRef
13.
go back to reference C. Schöfl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur. J. Endocrinol. 168, 39–47 (2013)CrossRef C. Schöfl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur. J. Endocrinol. 168, 39–47 (2013)CrossRef
14.
go back to reference Institute of Medicine. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. (National Academies Press Washington, DC, USA). U.S. Department of Health and Human Services, HIPAA Regul §164514 Institute of Medicine. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. (National Academies Press Washington, DC, USA). U.S. Department of Health and Human Services, HIPAA Regul §164514
15.
go back to reference M.P. Armstrong, G. Rushton, D.L. Zimmerman, Geographically masking health data to preserve confidentiality. Stat. Med. 18, 497–525 (1999)CrossRef M.P. Armstrong, G. Rushton, D.L. Zimmerman, Geographically masking health data to preserve confidentiality. Stat. Med. 18, 497–525 (1999)CrossRef
16.
go back to reference D.I. Gregorio, L.M. DeChello, H. Samociuk, M. Kulldorff, Lumping or splitting: seeking the preferred areal unit for health geography studies. Int. J. Health Geogr. 4(1), 6 (2005) D.I. Gregorio, L.M. DeChello, H. Samociuk, M. Kulldorff, Lumping or splitting: seeking the preferred areal unit for health geography studies. Int. J. Health Geogr. 4(1), 6 (2005)
17.
go back to reference A. Ben-Shlomo, M.C. Sheppard, J.M. Stephens, S. Pulgar, S. Melmed, Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284–294 (2011)CrossRef A. Ben-Shlomo, M.C. Sheppard, J.M. Stephens, S. Pulgar, S. Melmed, Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284–294 (2011)CrossRef
18.
go back to reference L.B. Porto, I.R. Zimmermann, L.A. Naves, Economics of acromegaly treatment in Brazil: a budget impact analysis of pituitary surgery compared with long‑term octreotide LAR. Pharmacoecon Open 3(2), 247–254 (2019)CrossRef L.B. Porto, I.R. Zimmermann, L.A. Naves, Economics of acromegaly treatment in Brazil: a budget impact analysis of pituitary surgery compared with long‑term octreotide LAR. Pharmacoecon Open 3(2), 247–254 (2019)CrossRef
22.
go back to reference A. Mestrón, S.M. Webb, R. Astorga, P. Benito, M. Catalá, S. Gaztambide et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004) A. Mestrón, S.M. Webb, R. Astorga, P. Benito, M. Catalá, S. Gaztambide et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004)
23.
go back to reference G. Sesmilo, S. Gaztambide, E. Venegas, A. Picó, C. Del Pozo, C. Blanco et al. Changes in acromegaly treatment over four decades in Spain: analysis of the spanish acromegaly registry (REA). Pituitary 16, 115–121 (2013)CrossRef G. Sesmilo, S. Gaztambide, E. Venegas, A. Picó, C. Del Pozo, C. Blanco et al. Changes in acromegaly treatment over four decades in Spain: analysis of the spanish acromegaly registry (REA). Pituitary 16, 115–121 (2013)CrossRef
24.
go back to reference M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167, 189–198 (2012)CrossRef M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167, 189–198 (2012)CrossRef
25.
go back to reference P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer 24, 505–518 (2017)CrossRef P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer 24, 505–518 (2017)CrossRef
26.
go back to reference S. Vallette, O. Serri, Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13, 311–314 (2010)CrossRef S. Vallette, O. Serri, Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13, 311–314 (2010)CrossRef
27.
go back to reference J. Roemmler, M. Bidlingmaier, J. Schopohl, Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant. Pituitary 13, 89–93 (2010)CrossRef J. Roemmler, M. Bidlingmaier, J. Schopohl, Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant. Pituitary 13, 89–93 (2010)CrossRef
28.
go back to reference L.A. Naves, L.B. Porto, J.W.C. Rosa, L.A. Casulari, J.W.C. Rosa, Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly. Pituitary 18(1), 8–15 (2015)CrossRef L.A. Naves, L.B. Porto, J.W.C. Rosa, L.A. Casulari, J.W.C. Rosa, Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly. Pituitary 18(1), 8–15 (2015)CrossRef
29.
go back to reference P. Petrossians, M.A. Tichomirowa, A. Stevenaert, D. Martin, A.F. Daly, A. Beckers, The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. Ann Endocrinol. (Paris) 73, 190–201 (2012)CrossRef P. Petrossians, M.A. Tichomirowa, A. Stevenaert, D. Martin, A.F. Daly, A. Beckers, The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. Ann Endocrinol. (Paris) 73, 190–201 (2012)CrossRef
30.
go back to reference P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur. J. Endocrinol. 152, 379–387 (2005)CrossRef P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur. J. Endocrinol. 152, 379–387 (2005)CrossRef
31.
go back to reference I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)CrossRef I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)CrossRef
32.
go back to reference M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans et al. AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)CrossRef M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans et al. AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)CrossRef
33.
go back to reference O. Kwon, Y.D. Song, S.Y. Kim, E.J. Lee, Nationwide survey of acromegaly in South Korea. Clin. Endocrinol. (Oxf.) 78, 577–585 (2013)CrossRef O. Kwon, Y.D. Song, S.Y. Kim, E.J. Lee, Nationwide survey of acromegaly in South Korea. Clin. Endocrinol. (Oxf.) 78, 577–585 (2013)CrossRef
34.
go back to reference R. Kauppinen-Mäkelin, T. Sane, A. Reunanen, M.J. Välimäki, L. Niskanen, H. Markkanen et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90, 4081–4086 (2005)CrossRef R. Kauppinen-Mäkelin, T. Sane, A. Reunanen, M.J. Välimäki, L. Niskanen, H. Markkanen et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90, 4081–4086 (2005)CrossRef
35.
go back to reference L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. García-Dominguez, A.A. Reza-Albarrán et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101, 3997–4004 (2016)CrossRef L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. García-Dominguez, A.A. Reza-Albarrán et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101, 3997–4004 (2016)CrossRef
36.
go back to reference A.L. Barkan, Radiotherapy in acromegaly: the argument against. Clin. Endocrinol. (Oxf.) 58, 132–135 (2003)CrossRef A.L. Barkan, Radiotherapy in acromegaly: the argument against. Clin. Endocrinol. (Oxf.) 58, 132–135 (2003)CrossRef
37.
go back to reference P.U. Freda, L. Katznelson, A.J. Van Der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 4465–4473 (2005)CrossRef P.U. Freda, L. Katznelson, A.J. Van Der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 4465–4473 (2005)CrossRef
38.
go back to reference L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)CrossRef L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)CrossRef
39.
go back to reference A. Colao, R.S. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19, 235–247 (2016)CrossRef A. Colao, R.S. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19, 235–247 (2016)CrossRef
40.
go back to reference R.S. Jallad, N.R. Musolino, S. Kodaira, V.A. Cescato, M.D. Bronstein, Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin. Endocrinol. (Oxf.) 67, 310–315 (2007)CrossRef R.S. Jallad, N.R. Musolino, S. Kodaira, V.A. Cescato, M.D. Bronstein, Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin. Endocrinol. (Oxf.) 67, 310–315 (2007)CrossRef
41.
go back to reference P. Petrossians, L. Borges-Martins, C. Espinoza, A. Daly, D. Betea, H. Valdes-Socin et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61–66 (2005)CrossRef P. Petrossians, L. Borges-Martins, C. Espinoza, A. Daly, D. Betea, H. Valdes-Socin et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61–66 (2005)CrossRef
42.
go back to reference N. Karavitaki, H.E. Turner, C.B.T. Adams, S. Cudlip, J.V. Byrne, V. Fazal-Sanderson et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin. Endocrinol. (Oxf.) 68, 970–975 (2008)CrossRef N. Karavitaki, H.E. Turner, C.B.T. Adams, S. Cudlip, J.V. Byrne, V. Fazal-Sanderson et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin. Endocrinol. (Oxf.) 68, 970–975 (2008)CrossRef
43.
go back to reference C.L. Boguszewski, M.K.P Huayllas, L. Vilar, L.A. Naves, A.R. Junior, B.S. Soares et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch. Endocrinol. Metab. 63(4), 328–336 (2019) C.L. Boguszewski, M.K.P Huayllas, L. Vilar, L.A. Naves, A.R. Junior, B.S. Soares et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch. Endocrinol. Metab. 63(4), 328–336 (2019)
46.
go back to reference M. Calovi, Using a GIS to support the spatial reorganization of outpatient care services delivery in Italy. BMC Health Serv. Res. 4, 1–16 (2018) M. Calovi, Using a GIS to support the spatial reorganization of outpatient care services delivery in Italy. BMC Health Serv. Res. 4, 1–16 (2018)
47.
go back to reference R.S. Kirby, E. Delmelle, J.M. Eberth, Advances in spatial epidemiology and geographic information systems. Ann. Epidemiol. 27(1), 1–9 (2017)CrossRef R.S. Kirby, E. Delmelle, J.M. Eberth, Advances in spatial epidemiology and geographic information systems. Ann. Epidemiol. 27(1), 1–9 (2017)CrossRef
Metadata
Title
Long-term real-life outcomes in a georrefered cohort of acromegalic patients in Brazil
Authors
Lara Benigno Porto
José Wilson Corrêa Rosa
João Willy Corrêa Rosa
Luiz Augusto Casulari
Ivan Ricardo Zimmermann
Luciana Ansaneli Naves
Publication date
01-05-2020
Publisher
Springer US
Published in
Endocrine / Issue 2/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02240-5

Other articles of this Issue 2/2020

Endocrine 2/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.